Patients with Waldenstrom Macroglobulinemia: We Need Your Help!
Lymphoma Canada is preparing a submission for the pan-Canadian Oncology Drug Review (pCODR) and the Quebec equivalent Institut national d’excellence en santé et services sociaux (INESSS) for an upcoming drug review on Zanubrutinib, also known as Brukinsa, for treatment naïve or relapsed/refractory Waldenstrom Macroglobulinemia.
If you have Waldenstrom Macroglobulinemia and have received Zanubrutinib, you can help by completing our survey. You can also participate in this survey if you have had treatment with another BTK inhibitor such as Ibrutinib. You CAN STILL participate if you have not received treatment with either of these therapies; we value the opportunity to learn about your lymphoma and its impacts on your quality of life.
The survey provides us with the patient input required for the submission. This information is used by pCODR and INESSS to help make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Friday, May 7, 2021, and should only take between 15-20 minutes of your time.
Please share and help us spread the word.
Thank you for your support.
